Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial

Macular Diseases

Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial

JAMA Ophthalmol

Khanani AM, Campochiaro PA, Graff JM, Marcus DM, Miller D, Mittra RA, Regillo C, Sheth VS, Bobbala A, Gune S, Lin S, Quezada-Ruiz C, Malhotra V

doi: 10.1001/jamaophthalmol.2025.0006

Macular DiseasesRetinal Diseases

Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial

JAMA Ophthalmol

Pieramici DJ, Awh CC, Chang M, Emanuelli A, Holekamp NM, Hu AY, Suñer IJ, Wykoff CC, Brittain C, Howard D, Quezada-Ruiz C, Santhanakrishnan A, Latkany P

doi: 10.1001/jamaophthalmol.2025.0001

Macular DiseasesRetinal Diseases

Faricimab Treat-and-Extend Dosing for Macular Edema due to Retinal Vein Occlusion: 72-Week Results From the BALATON and COMINO Trials

Ophthalmol Retina

Danzig CJ, Dinah C, Ghanchi F, Hattenbach LO, Khanani AM, Lai TYY, Shimura M, Abreu F, Arrisi P, Liu Y, Paris LP, Retiere AC, Willis JR, Schlottmann PG, BALATON and COMINO Investigators

doi: 10.1016/j.oret.2025.03.005

Macular Diseases

Race and Vision Outcomes in Ranibizumab-Treated Participants With Diabetic Macular Edema: A Meta-Analysis

JAMA Ophthalmol

Khan MA, Hill L, Stoilov I, Haller JA

doi: 10.1001/jamaophthalmol.2024.6371

Retinal Diseases

Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy

JAMA Ophthalmol

Alsoudi AF, Wai KM, Koo E, Parikh R, Mruthyunjaya P, Rahimy E

doi: 10.1001/jamaophthalmol.2024.3283

Macular Diseases

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

Ophthalmol Ther

Debourdeau E, Beylerian H, Nguyen V, Barthelmes D, Gillies M, Gabrielle PH, Vujosevic S, Otoole L, Puzo M, Creuzot-Garcher C, Wolff B, Daien V, Fight Retinal Blindness! Study Group

doi: 10.1007/s40123-024-00983-2

Macular Diseases

Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents

J Clin Med

Sugimoto M, Chujo S, Kato K, Shimura M, Kitano S, Kusuhara S, Terasaki H, Kondo M, Writing Committee Of Japan-Clinical Retina Study Group J-Crest

doi: 10.3390/jcm13237336

Macular Diseases

Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial

JAMA Ophthalmol

Murphy GSP, Saleh A, Ayis S, Cheema MR, Mehta A, Steel DH, Membrey L, Costen M, Jackson TL

doi: 10.1001/jamaophthalmol.2024.4297

Macular Diseases

Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema-A Swiss Cohort Study

Pharmaceuticals (Basel)

Turgut F, Somfai GM, Tappeiner C, Hatz K, Mantel I, Ambresin A, Donati G, Guignard V, Nagyová D, Pfister IB, Schild C, Garweg JG

doi: 10.3390/ph17091235

Related content

Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial

Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial

Faricimab Treat-and-Extend Dosing for Macular Edema due to Retinal Vein Occlusion: 72-Week Results From the BALATON and COMINO Trials

Race and Vision Outcomes in Ranibizumab-Treated Participants With Diabetic Macular Edema: A Meta-Analysis

Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents

Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial

Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema-A Swiss Cohort Study